ArticleGynecologic oncology reports2026
Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mirvetuximab Soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα), expressed in most ovarian cancers. Pivotal trials reported favorable outcomes but used stringent eligibility criteria, and real-world effectiveness and toxicity remain incompletely characterized. We evaluated overall survival (OS), progression-free survival (PFS), and toxicity among a general gynecologic oncology population treated with MIRV for recurrent ovarian cancer. Methods: This retrospective study analyzed data from patients with recurrent ovarian cancer who received MIRV at a tertiary NCI-designated cancer center and an affiliated private hospital between November 2022 and April 2025. Demographics, disease and treatment characteristics, and toxicities were abstracted from the electronic medical record. OS and PFS were estimated using the Kaplan-Meier method. Multivariable Cox proportional hazards models assessed associations between clinical factors and survival. Results: Sixty-six patients received MIRV. Most had stage IIIC-IVB disease (89%), 86% had a PS of 0 or 1, and 77% had received ≥3 prior therapeutic regimens. Most (52%) had platinum-resistant disease, and FRα expression was positive in 77% of cases. Median OS was 16.4 months (95% CI 12.4 to NE) and PFS was 5.3 months (95% CI 4.1-7.1). OS and PFS did not differ by platinum status. ECOG PS >1 was associated with worse OS (median 6.0 vs 20.3 months for PS 0-1; Conclusion: MIRV demonstrates clinically meaningful survival, but outcomes are strongly influenced by performance status. Patients with ECOG PS >1 should be counseled about substantially shorter survival, and clinicians should anticipate and manage MIRV toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.